Success Rate and Risk Factors for Failure of Empirical Antifungal Therapy with Itraconazole in Patients with Hematological Malignancies: A Multicenter, Prospective, Open-Label, Observational Study in Korea

Soo-Jeong KIM; June-Won CHEONG; Yoo-Hong MIN; Young-Jin CHOI; Dong-Gun LEE; Je-Hwan LEE; Deok-Hwan YANG; Sang-Min LEE; Sung-Hyun KIM; Yang-Soo KIM; Jae-Yong KWAK; Jinny PARK; Jin-Young KIM; Hoon-Gu KIM; Byung-Soo KIM; Hun-Mo RYOO; Jun-Ho JANG; Min-Kyoung KIM; Hye-Jin KANG; In-Sung CHO; Yeung-Chul MUN; Deog-Yeon JO; Ho-Young KIM; Byeong-Bae PARK; Jin-Seok KIM.
Journal of Korean Medical Science ; : 61-68, 2014.
Artículo en Inglés | WPRIM | ID: wpr-200225

Documentos relacionados

  1. Success rate and risk factors for failure of empirical antifungal therapy with itraconazole in patients with hematological malignancies: a multicenter, prospective, open-label, observational study in Korea.
  2. Echinocandins versus non-echinocandins for empirical antifungal therapy in patients with hematological disease with febrile neutropenia: A systematic review and meta-analysis.
  3. The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observational study in Korea.
  4. Assessment of Antimicrobial Utilization among Cancer Patients with Febrile Neutropenia at the Lebanese Hospitals.
  5. Comparison of micafungin and voriconazole as empirical antifungal therapies in febrile neutropenic patients with hematological disorders: a randomized controlled trial.
  6. Fatal disseminated Trichosporon asahii fungemia in a child with acute lymphoblastic leukemia and a morbilliform eruption.
  7. Is preemptive antifungal therapy a good alternative to empirical treatment in prolonged febrile neutropenia?
  8. A multicenter phase 2 study of empirical low-dose liposomal amphotericin B in patients with refractory febrile neutropenia.
  9. Risk Factors and Outcomes in Critically Ill Patients with Hematological Malignancies Complicated by Hospital-Acquired Infections.
  10. Dermatological manifestations of fungal infection in patients with febrile neutropaenia: A review of the literature.